Henry Schein Inc. (HSIC) Given “Outperform” Rating at Robert W. Baird
Robert W. Baird restated their outperform rating on shares of Henry Schein Inc. (NASDAQ:HSIC) in a research report report published on Tuesday morning. They currently have a $176.00 price target on the stock, up from their prior price target of $175.00.
A number of other equities analysts also recently issued reports on HSIC. Zacks Investment Research downgraded Henry Schein from a buy rating to a hold rating in a report on Tuesday, July 5th. Bank of America Corp. started coverage on Henry Schein in a report on Monday, September 12th. They issued a buy rating and a $185.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $157.92.
Henry Schein (NASDAQ:HSIC) traded up 0.54% during midday trading on Tuesday, hitting $160.91. The stock had a trading volume of 135,793 shares. The firm has a market cap of $13.16 billion, a price-to-earnings ratio of 27.26 and a beta of 1.05. The firm has a 50 day moving average of $162.59 and a 200 day moving average of $170.62. Henry Schein has a 52 week low of $136.01 and a 52 week high of $183.00.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Thursday, August 4th. The company reported $1.64 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.01. The company earned $2.87 billion during the quarter, compared to the consensus estimate of $2.85 billion. Henry Schein had a return on equity of 17.84% and a net margin of 4.42%. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.46 earnings per share. Equities research analysts predict that Henry Schein will post $6.57 EPS for the current year.
In other news, Director Paul Brons sold 3,381 shares of the firm’s stock in a transaction dated Monday, August 29th. The stock was sold at an average price of $164.03, for a total value of $554,585.43. Following the transaction, the director now owns 13,715 shares of the company’s stock, valued at $2,249,671.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.27% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Henry Schein by 2.2% in the second quarter. Vanguard Group Inc. now owns 7,493,463 shares of the company’s stock valued at $1,324,844,000 after buying an additional 161,065 shares during the period. BlackRock Fund Advisors increased its stake in shares of Henry Schein by 2.4% in the second quarter. BlackRock Fund Advisors now owns 2,369,132 shares of the company’s stock valued at $418,863,000 after buying an additional 55,384 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in shares of Henry Schein by 0.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 2,342,943 shares of the company’s stock valued at $404,462,000 after buying an additional 8,593 shares during the period. Janus Capital Management LLC increased its stake in shares of Henry Schein by 16.5% in the second quarter. Janus Capital Management LLC now owns 2,027,848 shares of the company’s stock valued at $358,522,000 after buying an additional 286,929 shares during the period. Finally, UBS Asset Management Americas Inc. increased its stake in shares of Henry Schein by 55.7% in the second quarter. UBS Asset Management Americas Inc. now owns 802,401 shares of the company’s stock valued at $141,865,000 after buying an additional 286,976 shares during the period. 91.98% of the stock is currently owned by institutional investors.
About Henry Schein
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.